Plasma ctDNA enhances the tissue-based detection of oncodriver mutations in colorectal cancer.

ABSTRACT:

Purpose

The advent of circulating tumor DNA (ctDNA) technology has provided a convenient and noninvasive means to continuously monitor cancer genomic data, facilitating personalized cancer treatment. This study aimed to evaluate the supplementary benefits of plasma ctDNA alongside traditional tissue-based next-generation sequencing (NGS) in identifying targetable mutations and tumor mutational burden (TMB) in colorectal cancers (CRC).

Methods

Our study involved 76 CRC patients, collecting both tissue and plasma samples for NGS. We assessed the concordance of gene mutational status between ctDNA and tissue, focusing on actionable genes such as KRAS, NRAS, PIK3CA, BRAF, and ERBB2. Logistic regression analysis was used to explore variables associated with discordance and positi

SUBMITTER: Wang W 

PROVIDER: S-EPMC11249419 | biostudies-literature | 2024 Aug

REPOSITORIES: biostudies-literature